Education and Training
OPsumit USers Registry
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Opsumit (macitentan)
Eligibility
Inclusion Criteria:
Patients newly treated with Opsumit defined as a new user of therapy, initiated ≤ 30 days
prior to enrollment visit.
Signed ICF
Exclusion Criteria:
Previous user of Opsumit defined as patient who initiated therapy >30 days prior to
enrollment.
Patients enrolled in any ongoing clinical trials
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting